UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

How Do the Accrual Pattern and Follow‐Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?

The oncologist (Dayton, Ohio), 2019-07, Vol.24 (7), p.867-871

2019

Volltextzugriff (PDF)

A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time‐to‐event data in randomized clinical trials

Statistics in medicine, 2018-07, Vol.37 (15), p.2307-2320

2018

Volltextzugriff (PDF)

Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology

Clinical trials (London, England), 2020-12, Vol.17 (6), p.597-606

2020

Volltextzugriff (PDF)

Ratio and difference of average hazard with survival weight: New measures to quantify survival benefit of new therapy

Statistics in medicine, 2023-03, Vol.42 (7), p.936-952

2023

Volltextzugriff (PDF)

Latinas in medicine: evaluating and understanding the experience of Latinas in medical education: a cross sectional survey

BMC medical education, 2024-01, Vol.24 (1), p.4-4, Article 4

2024

Volltextzugriff (PDF)

On permutation tests for comparing restricted mean survival time with small sample from randomized trials

Statistics in medicine, 2020-09, Vol.39 (20), p.2655-2670

2020

Volltextzugriff (PDF)

Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study

JAMA oncology, 2018-06, Vol.4 (6), p.881

2018

Volltextzugriff (PDF)

Biomarkers in Oncology: Complexities in Biomarker-Driven Studies and Statistical Analysis

JCO precision oncology, 2024-07, Vol.8 (8), p.e2400358

2024

Volltextzugriff (PDF)

On assessing survival benefit of immunotherapy using long‐term restricted mean survival time

Statistics in medicine, 2023-04, Vol.42 (8), p.1139-1155

2023

Volltextzugriff (PDF)

Vascular injury markers associated with cognitive impairment in people with HIV on suppressive antiretroviral therapy

AIDS (London), 2023-11, Vol.37 (14), p.2137-2147

2023

Volltextzugriff (PDF)

Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time‐to‐Event Outcomes

The oncologist (Dayton, Ohio), 2020-02, Vol.25 (2), p.91-93

2020

Volltextzugriff (PDF)

Suggestions on Using Machine Learning Models and Cautions for Analyzing Censored Time-To-Event Outcomes

JCO precision oncology, 2024-05, Vol.8 (8), p.e2400220

2024

Volltextzugriff (PDF)

Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment

Journal of clinical oncology, 2018-03, Vol.36 (7), p.720-721

2018

Volltextzugriff (PDF)

Regression models for average hazard

Biometrics, 2024-03, Vol.80 (2)

2024

Volltextzugriff (PDF)

GUIAR: Promoting lung cancer screening in Hispanic head and neck cancer survivors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl)

2024

Volltextzugriff (PDF)

Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer

Journal of clinical oncology, 2018-03, Vol.36 (8), p.825-826

2018

Volltextzugriff (PDF)

Familial Burden and Other Clinical Factors Associated With Various Types of Cancer in Individuals With Lynch Syndrome

Gastroenterology (New York, N.Y. 1943), 2021-07, Vol.161 (1), p.143-150.e4

2021

Volltextzugriff (PDF)

Going back home: Understanding the challenges of international medical graduates (IMGs) in oncology

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.9001-9001

2024

Volltextzugriff (PDF)

Assessing gender disparities in oncology: Less talk, more action

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.9011-9011

2024

Volltextzugriff (PDF)

Recent Discussions on Statistical Analysis Methods in Cancer Clinical Trials and Their Application to Pharmaceutical Sciences: Issues of Hazard Ratio and an Alternative Summary Measure

Iryo yakugaku, 2018-12, Vol.44 (12), p.589-598

2018

Volltextzugriff (PDF)

Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival

Journal of clinical oncology, 2018-05, Vol.36 (13), p.1378-1379

2018

Volltextzugriff (PDF)

What is your preferred language? Evaluating equal access to oncology clinical studies for non-English-speaking participants

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6547-6547

2023

Volltextzugriff (PDF)

Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer

Journal of clinical oncology, 2017-10, Vol.35 (29), p.3373-3373

2017

Volltextzugriff (PDF)

Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment

Journal of clinical oncology, 2022-12, Vol.40 (35), p.4083-4094

2022

Volltextzugriff (PDF)

Are we doing it right? Mentorship challenges for oncology fellows and early-career faculty from backgrounds underrepresented in medicine

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.11047-11047

2022

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(73)
Tagungsberichte
(1)

Sprache

Englisch
(67)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(35)
Humans
(24)
Female
(16)
Oncology
(14)
Male
(12)
Middle Aged
(9)
Adult
(7)
Physical Sciences
(7)
Aged
(6)
Animals
(6)
Mathematical & Computational Biology
(5)
Mathematics
(5)
Medicine, Research & Experimental
(5)
Public, Environmental & Occupational Health
(5)
Research & Experimental Medicine
(5)
Statistics & Probability
(5)
Biological And Medical Sciences
(4)
Germ-Line Mutation
(4)
Medical Informatics
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

How Do the Accrual Pattern and Follow‐Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?

A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time‐to‐event data in randomized clinical trials

Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology

Ratio and difference of average hazard with survival weight: New measures to quantify survival benefit of new therapy

Latinas in medicine: evaluating and understanding the experience of Latinas in medical education: a cross sectional survey

On permutation tests for comparing restricted mean survival time with small sample from randomized trials

Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study

Biomarkers in Oncology: Complexities in Biomarker-Driven Studies and Statistical Analysis

On assessing survival benefit of immunotherapy using long‐term restricted mean survival time

Vascular injury markers associated with cognitive impairment in people with HIV on suppressive antiretroviral therapy

Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time‐to‐Event Outcomes

Suggestions on Using Machine Learning Models and Cautions for Analyzing Censored Time-To-Event Outcomes

Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment

Regression models for average hazard

GUIAR: Promoting lung cancer screening in Hispanic head and neck cancer survivors

Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer

Familial Burden and Other Clinical Factors Associated With Various Types of Cancer in Individuals With Lynch Syndrome

Going back home: Understanding the challenges of international medical graduates (IMGs) in oncology

Assessing gender disparities in oncology: Less talk, more action

Recent Discussions on Statistical Analysis Methods in Cancer Clinical Trials and Their Application to Pharmaceutical Sciences: Issues of Hazard Ratio and an Alternative Summary Measure

Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival

What is your preferred language? Evaluating equal access to oncology clinical studies for non-English-speaking participants

Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer

Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment

Are we doing it right? Mentorship challenges for oncology fellows and early-career faculty from backgrounds underrepresented in medicine

Suchergebnisse filtern